Our latest
Press Releases & Updates

Latest press releases

RetinAI Announces Strategic Partnership with Eyestem to Innovate Geographic Atrophy Clinical Research Using State-of-the-Art AI Technology

RetinAI and Retina Consultants of America Join Forces to build the Most Comprehensive U.S.-based Real World Evidence Database in Ophthalmology

RetinAI Medical AG and Retina Consultants of America (RCA) forge a strategic partnership to revolutionize Ophthalmology data. Leveraging RetinAI's advanced AI technologies and RCA's expansive clinic network, this alliance is set to develop the largest Real World Evidence (RWE) U.S.-based database in the field.

RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence

RetinAI Medical AG has announced a partnership with Boehringer Ingelheim to improve patient outcomes in geographic atrophy (GA). RetinAI's AI tools for identifying novel biomarkers will be used to analyze Boehringer Ingelheim's imaging datasets from clinical studies and real-world evidence to identify additional biomarkers and predictors of disease progression. This partnership aims to accelerate the development of novel treatments and enable earlier and more precise diagnosis, contributing to Boehringer Ingelheim's vision of preventing vision loss and blindness caused by retinal diseases.

RetinAI’s AI Algorithms Enrich Clinical Research and Improve Patient Care

RetinAI Medical AG has announced the acceptance of five abstracts for poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) conference taking place from April 23rd to 26th, 2023 in New Orleans. These studies highlight the potential of RetinAI’s Discovery platform and its certified and research use only (RUO) AI models to revolutionize healthcare decisions, improve patient care, help accelerate clinical trials, and drive better decisions for patient management.

Latest updates

Fully-automated atrophy segmentation in dry age-related macular degeneration in optical coherence tomography - Scientific Reports

RetinAI is thrilled to introduce our novel method for the segmentation of atrophy with performance matching human experts published in Scientific Reports and developed in collaboration with the Fondation Asile des aveugles, Hôpital ophtalmique Jules-Gonin in Lausanne. Congratulations to both teams for this success!

Full Article -

Authors: Yasmine Derradji, Agata Mosinska, Stefanos Apostolopoulos, Carlos Ciller, Sandro De Zanet & Irmela Mantel Widmer

Automatic Atrophy Progression Prediction in Age-Related Macular Degeneration in EURETINA 2021

We are happy to present our novel method for prediction of continuous atrophy growth for follow-up periods of 4 years and longer in this year's EURETINA 2021. Congratulations to our collaborators and team members for this great poster.

We enable for the first time the creation of atrophy risk maps, which present the risk of retinal regions being affected by the atrophy in the future.

Authors: Agata Mosinska, Anthony Gigon, Stefanos Apostolopoulos, Carlos Ciller, Irmela Mantel Widmer, Sandro De Zanet

RetinAI in Top 100 Swiss Startups for 2021

RetinAI is proud to be recognized as one of the TOP 100 Swiss Startups for 2021. Check out the ‘Hall of Fame’ on to see Retinai again in the list this year.

Huge thanks to everyone in the team, to our supporters, and to our partners for believing in us along the way and for supporting us to define the future of Digital Precision Medicine!

First Peer-reviewed Publication around the RAZORBILL Study

The very first peer-reviewed publication around the RAZORBILL study has been published in the British journal of Ophthalmology (BJO).

'Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study'

A first of its class international multi-center clinical study to assess the influence of automated 3D OCT scan enrichment with segmentation information on disease activity assessment in patients with nAMD treated with either brolucizumab, ranibizumab or aflibercept.

We are glad to be supporting this initiative together with a leading team of world renown ophthalmologists & Novartis!

Contact us for more informations! We are happy to hear from you!